SKIN logo

SKINHEALTH SYSTEMS INC

SKINNASDAQ
πŸ† #4183 by market capEarnings Nov 4 Β· PostUS Equity
$0.63β–Ό $0.02 (βˆ’3.11%)
After hours Β· at close
πŸ””
Track SKIN
Get earnings, price moves & breaking news on Telegram
Track
24hβ–Ό 3.1%
7dβ–Ό 6.1%
14dβ–Ό 6.8%
30dβ–Ό 8.1%
ytdβ–Ό 54.4%
1yβ–Ό 68.7%
🏦Market Cap
$82M
Small Cap
πŸ“ˆRevenue Growth (YoY)
-10.0%
Declining
πŸ“ŠGross Margin
66.3%
High
πŸ’΅FCF Margin
5.7%
Moderate
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
84
Good

Trading Snapshot

Day Range
$0.63 – $0.63
52-Week Range
$0.55 – $2.03
Volume
$2.90B
Avg Volume
$2.86B
Shares Outstanding
129.6M
Next Earnings
Oct 25, 2026

Fundamentals Snapshot

Annual Revenue
$301M
Last Q Revenue
$72M
P/E Ratio
-2.9
P/S Ratio
0.3x
EPS (TTM)
$-0.22
Dividend Yield
0.00%
Dilution (1yr)
+2.4%

Why Investors Own SKIN

  • βœ“High-growth profile β€” revenue up +54.7% YoY with expanding US Equity exposure.
  • βœ“Healthy economics β€” 60% gross margin and 20% free-cash-flow margin.
  • βœ“New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SKIN logo

SKINHEALTH SYSTEMS INC

SKIN
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$301Mβ–Ό βˆ’10.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
65.3%β–² +19.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$21Mβ–Ό βˆ’69.3% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$32Mβ–² +246.1% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
127.4Mβ–² +2.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$146Mβ–² +$52M YoY
StockOtter Β· stockotter.space

About SKINHEALTH SYSTEMS INC

SkinHealth Systems Inc., a global medical aesthetics company delivering an integrated ecosystem of clinically proven solutions in the Americas, the Asia-Pacific, Europe, the Middle East, Africa, Canada, and Latin America. The company's flagship product is HydraFacial, which enhances the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. It also offers Syndeo devices, which are delivery systems that are designed to connect providers to the consumer's preferences to create a more personalized experience; consumables, such as single-use tips, solutions, and serums used to provide a hydrafacial treatment; SkinStylus SteriLock Microsystem, a microneedling and nanoneedling device used for the treatment of enhancing appearance of surgical or traumatic hypertrophic scars on the abdomen and facial acne scarring in Fitzpatrick skin types I, II, and III; and Keravive peptide solutions and take home sprays for treating scalp health. In addition, it operates the MyBeautyHealth mobile application for consumers to earn loyalty points and unlock savings, log skin concerns and receive personalized treatment plans, and find and connect with Hydrafacial providers, as well as offers boosters. The company was formerly known as The Beauty Health Company and changed its name to SkinHealth Systems Inc. in April 2026. The company was founded in 1997 and is headquartered in Long Beach, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Good
84/100

Analyst Ratings

β“˜
Consensus
Hold
14 analysts
Strong Buy0
Buy1
Hold8
Sell3
Strong Sell2
Ratings as of Sep 2026

Latest News & Updates